Akoya Biosciences, which provides spatial biology solutions for discovery and clinical research, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
Akoya delivers spatial biology solutions focused on transforming discovery and clinical research. Through its CODEX and Phenoptics platforms, reagents, software and services, the company offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum, from discovery through translational and clinical research.
The Marlborough, MA-based company was founded in 2015 and booked $42 million in revenue for the 12 months ended December 31, 2020. It plans to list on the Nasdaq under the symbol AKYA. Akoya Biosciences filed confidentially on February 5, 2021. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.